MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register
About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Industry news

Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer

In order to access this content you must be logged in and have a subscription to PL Intelligence.

PLi

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.

Subscribe now for instant access to the benefits PL Intelligence has to offer. Find out more.

Company details

If you want to find out more about the company visit Acceleron Pharma profile.

Related news

Latest News

CML HealthCare Income Fund Reports 2009 Third Quarter Financial Results
Lonza successfully develops a manufacturing process for ArzerraTM (ofatumumab), a new biopharmaceutical from GSK and Genmab
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
CML HealthCare Income Fund Announces Release Date for Fiscal 2009 Third Quarter Financial Results
ORTHO CLINICAL DIAGNOSTICS LAUNCHES FETALSCREEN(TM) II FETAL MATERNAL HEMORRHAGE SCREENING TEST
Diagnostics HemoCue Subsidiary to Add U.S. Hospital Laboratory Connectivity to Its HemoCue 201 DM Point-of-Care Systems
University of Southern California receives $1 million NIH grant to study TXA127 for the prevention of radiation damage
Tarix Pharmaceuticals receives FDA approval for Phase 2 study to mitigate chemotherapy-induced thrombocytopenia
More news... | RSS Feed...

Most Viewed

Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer

Tarix Pharmaceuticals receives FDA approval for Phase 2 study to mitigate chemotherapy-induced thrombocytopenia

Lonza successfully develops a manufacturing process for ArzerraTM (ofatumumab), a new biopharmaceutical from GSK and Genmab

CML HealthCare Income Fund Reports 2009 Third Quarter Financial Results

CML HealthCare Income Fund Announces Release Date for Fiscal 2009 Third Quarter Financial Results

University of Southern California receives $1 million NIH grant to study TXA127 for the prevention of radiation damage

Diagnostics HemoCue Subsidiary to Add U.S. Hospital Laboratory Connectivity to Its HemoCue 201 DM Point-of-Care Systems

ORTHO CLINICAL DIAGNOSTICS LAUNCHES FETALSCREEN(TM) II FETAL MATERNAL HEMORRHAGE SCREENING TEST

Therapeutic Target

Cardiovascular
Dermatology
Endocrine and Metabolic
Gastroenterology
Genitourinary
Hematology
Immunology and Allergy
Infection
Musculoskeletal
Neurology
Obstetrics and Gynecology
Oncology
Ophthalmology
Psychiatry
Pulmonary

Categories

Deals and Alliances
Development
Financial Results
Financings
Intellectual Property
Regulatory
Press releases
Deals review
Headlines
PR Newswire

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Profile your company today
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us